Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
How does ivermectin cross the blood-brain barrier in humans?
Executive summary
Ivermectin normally does not enter the human brain in appreciable amounts because active efflux transporters—principally P‑glycoprotein encoded by MDR1/ABCB1—pump it back across the blood‑brain barrier (BBB), so brain levels are low except in overdose or when the BBB or transporter function is impaired (see [1], p1_s4). Animal models lacking P‑glycoprotein show up to ~90‑fold higher brain ivermectin, and related clinical reports link neurotoxicity to transporter defects, overdose, or BBB compromise [1] [2] [3].
1. How the blood‑brain barrier normally blocks ivermectin
The BBB is formed by tightly joined brain capillary endothelial cells that create a lipophilic and transporter‑regulated barrier; ivermectin is relatively lipophilic but is efficiently excluded from the CNS by efflux pumps—mainly P‑glycoprotein—located on the blood side of endothelial cells, which actively pump ivermectin back into the circulation and thereby limit its passive and net entry into brain tissue [4] [5] [2].
2. The central role of P‑glycoprotein (MDR1/ABCB1)
Multiple experimental and review articles state that P‑glycoprotein (also called MDR1 or ABCB1) is the key mechanism restricting ivermectin brain penetration: it is an ATP‑driven efflux pump and its expression at the BBB explains why ivermectin “penetrates the mammalian brain poorly” under normal conditions [2] [3] [5]. When P‑glycoprotein function is lost or inhibited, ivermectin accumulates in brain tissue and can produce neurotoxic signs [1] [3].
3. Evidence from knockout animals and sensitive breeds
Knockout mice lacking the mdr1 gene show dramatically increased brain ivermectin—reports cite as much as a 90‑fold rise compared with normal mice—demonstrating causality between loss of P‑glycoprotein and CNS accumulation [1] [2]. Veterinary medicine supplies parallel evidence: collie‑breed dogs with an MDR1 mutation accumulate ivermectin in the brain and develop severe neurotoxicity, a real‑world analogue of human transporter deficiency [1] [2].
4. When ivermectin can cross into the brain in humans
Available sources describe three main scenarios in which ivermectin can reach higher brain levels: very high (toxic/overdose) systemic concentrations; impaired BBB integrity (for example, due to inflammation or other illness); and reduced P‑glycoprotein function (genetic variants, drug interactions that inhibit P‑gp, or disease‑related downregulation) [1] [3] [6]. Case reports and reviews note encephalopathy and other CNS events in such contexts, although they treat these as atypical and typically linked to the listed risk factors [1] [7].
5. Pharmacokinetic modifiers and binding that affect uptake
Protein binding (albumin) and hepatic metabolism also influence circulating free ivermectin available to interact with the BBB: in vitro work with bovine brain endothelial cells shows that albumin markedly reduces ivermectin uptake into endothelial cells, implying that changes in plasma protein binding or high free drug fraction could alter brain exposure [8]. Ivermectin is metabolized by CYP enzymes, so interactions that raise plasma levels could theoretically increase CNS exposure if efflux is overwhelmed [5] [8].
6. What the literature does not resolve or overstates
Available reporting consistently emphasizes poor brain penetration under normal conditions [9] [10], but specifics about human genetic variability in MDR1, the clinical frequency of transporter‑related encephalopathy, and exact concentration thresholds for CNS effects in humans are not fully detailed in the cited sources—those data are described largely from animal models, veterinary cases, and case series rather than large controlled human pharmacokinetic studies [1] [2] [3]. Claims that ivermectin readily crosses the human BBB in routine dosing are not supported by these sources [5] [10].
7. Competing viewpoints and implicit agendas to note
Clinical and toxicology reviews present a consensus that P‑glycoprotein protects the human brain from ivermectin and that CNS toxicity is uncommon in standard use [5] [10]. Some public‑facing materials (e.g., FAQs addressing off‑label COVID claims) emphasize rare encephalopathy reports and suggest possible BBB crossing in inflammatory states—these pieces aim to caution against misuse and may stress risk to counter misinformation [6]. Conversely, veterinary literature and knockout models demonstrate clear vulnerability when efflux is absent, an argument used both to explain rare human events and to caution clinicians [1] [3].
8. Bottom line for clinicians and the public
Under normal clinical dosing, ivermectin is kept out of the human brain primarily by P‑glycoprotein at the BBB and therefore seldom produces CNS effects; exceptions occur with overdose, impaired BBB, or defective/inhibited efflux, situations documented in animal models, veterinary genetics, and human case series [5] [1] [2]. If you are concerned about interactions, genetic susceptibility, or neurologic symptoms after ivermectin exposure, current sources recommend treating those contexts as higher risk and investigating for overdose, co‑medications that inhibit P‑gp, or BBB‑compromising conditions [1] [3].